Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03391778 · ClinicalTrials.gov registry record · Phase 1
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
A Phase 1 study of Neoplasms, sponsored by Uswm CT.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT03391778: Recruiting Phase 1 study of Neoplasms, sponsored by Uswm CT.
NCT03391778 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Uswm CT. The registered enrollment target is 250 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03391778, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Uswm CT.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Conditions Studied
Interventions
- BIOLOGICAL ADP adoptive cell therapy
Study Locations (20)
Maryland
- ADP Investigational Site - Baltimore
- National Cancer Institute - Center for Cancer Research - Bethesda
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
- University of Texas MD Anderson Cancer Center - Houston
Georgia
- Emory University School of Medicine - Atlanta
Michigan
- University of Michigan - Ann Arbor
Missouri
- Washington University School of Medicine in St. Louis - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2032-04-01 |
| Phase | Phase 1 |
What NCT03391778 shows while recruiting
NCT03391778 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which ADP adoptive cell therapy is the first listed.
NCT03391778 names 20 study sites across 17 states, led by Maryland, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT03391778 about?
NCT03391778 is a clinical study titled "Adoptive Cell Therapy Long-term Follow-up (LTFU) Study". This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
What is the current status of trial NCT03391778?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2018-04-09. Estimated completion is 2032-04-01.
What conditions does trial NCT03391778 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03391778?
The interventions under investigation include: ADP adoptive cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03391778?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03391778 being conducted?
This trial has 20 study locations across Georgia, Maryland, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03391778's enrollment target sits among peer trials
250 39th of 158 higher than 120 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI